4月17日，据CDE官网消息，武汉人福创新药物研发中心有限公司联合申请药品“HWS116注射液”，获得临床试验默示许可，受理号CXSL2500125。
公示信息显示，药品“HWS116注射液”适应症：晚期实体瘤。
武汉人福创新药物研发中心有限公司，成立于2020年，位于武汉市，是一家以从事研究和试验发展为主的企业。企业注册资本2000万人民币，实缴资本2000万人民币。
通过天眼查大数据分析，武汉人福创新药物研发中心有限公司专利信息132条，此外企业还拥有行政许可3个。
主要股东信息显示，武汉人福创新药物研发中心有限公司由人福医药集团股份公司持股100%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.